ARTICLE | Company News
J&J submits U.S., EU applications for siltuximab
September 4, 2013 12:39 AM UTC
The Janssen R&D LLC subsidiary of Johnson & Johnson (NYSE:JNJ) submitted a BLA to FDA and an MAA to EMA for siltuximab ( CNTO 328) to treat multicentric Castleman's disease (MCD) in patients who are HIV- and human herpes virus-8 (HHV-8)-negative. The chimeric mAb against IL-6 is in Phase II testing for the indication. Siltuximab also is in Phase II testing for multiple myeloma (MM) and has completed a Phase II trial for metastatic prostate cancer that did not respond to hormone therapy. ...